Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force
05/05/2025 13:24
May 5 (Reuters) - UNITY Biotechnology Inc UBX.O: UNITY BIOTECHNOLOGY INC - COMPANY ESTIMATES $3.7 MILLION CASH EXPENSES FOR REDUCTION IN FORCE - SEC FILING UNITY BIOTECHNOLOGY INC - REDUCTION IN FORCE EXPECTED TO BE COMPLETED BY MAY 15, 2025 - SEC FILING UNITY BIOTECHNOLOGY INC - CEO ANIRVAN GHOSH, CFO LYNNE SULLIVAN, AND ALEXANDER NGUYEN TO TERMINATE EMPLOYMENT - SEC FILING Source text: [ID:n0000950170-25-063167] Further company coverage: UBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force